Earnings blowout, massive guidance hike, and $2B buyback expansion send hospital operator surging — Quick Take
Tenet Healthcare rocketed +17.2% on July 25 — the single largest turnover name ($1B) on the US VolumeSurge screener — after reporting Q2 2026 adjusted EPS of $6.12 vs $4.26 consensus on $5.63B in revenue. The company raised FY2026 EPS guidance to $20.30–$21.69 (from $16.38–$18.68), well above the $17.88 analyst consensus, and expanded its share repurchase authorization by $2.0B. Healthcare was the #3 sector on the US VolumeSurge board with 7 stocks passing all filters, and THC led them all by turnover and news impact.
| Year | Revenue | Rev Growth | Op Margin | Net Income |
|---|---|---|---|---|
| FY2022 | $19.2B | — | 12.2% | $411M |
| FY2023 | $20.5B | +7.2% | 12.2% | $611M |
| FY2024 | $20.7B | +0.6% | 28.8%¹ | $3,200M¹ |
| FY2025 | $21.3B | +3.1% | ~13% | ~$1,500M |
| TTM (2Q26) | $21.9B | +2.6% | ~15% | ~$2,100M |
¹ FY2024 includes significant non-recurring gains from hospital portfolio restructuring. Normalized operating margin runs ~13–15%. TTM and forward estimates based on Q2 2026 results and updated company guidance.
Tenet delivered across every line. Revenue of $5.63B (+6.8% YoY) was powered by same-store ambulatory growth of +5.0% (net patient revenue per case +6.3%) and hospital revenue of $4.24B (+6.0%). Adjusted EBITDA hit $1.304B — a 23.2% margin — while GAAP net income reached $826M. The ambulatory segment (USPI) posted revenue of $1.39B (+9.3%), driven by higher-acuity procedures, facility acquisitions, and expanded service lines.
CEO Saum Sutaria flagged "strong same-store revenue growth and effective expense management" as the core drivers, while acknowledging ongoing headwinds from payer mix shifts — specifically declining Exchange admissions and Medicaid disenrollments in states like California. The company offset these with commercial employer revenue strength and higher Medicaid supplemental payments.
THC appeared as the #1 US VolumeSurge pick on July 25 with +17.2% daily gain, $1.0B turnover, and P/E of 9 (pre-surge). The stock cleared all three momentum filters: ≥5% daily gain, 30MA upward slope, and positive equity. Healthcare overall had 7 stocks pass all filters, ranking #3 behind Technology (10) and Financial Services (8).
Tenet Healthcare delivered a genuinely impressive quarter that forces a re-rating of a stock the market had priced for stagnation. At 11x forward earnings with a $2B buyback, the value case is straightforward — if you believe the earnings quality is sustainable. The risk is that payer mix deterioration and policy uncertainty eat into margins over the next 12–18 months, and that FY2024's one-time gains left investors overly skeptical of reported numbers. For patient value investors comfortable with healthcare complexity, THC at these levels is interesting. The buyback alone provides a meaningful floor. But this isn't a set-it-and-forget-it name — it requires monitoring the quarterly payer mix data closely.
Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings, financial data providers, and the Sazabi Research VolumeSurge screener. All financials are approximate and should be verified against official SEC filings.